Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of T Cell Receptor-Redirected T Cells Infusions for Preventing Hepatocellular Carcinoma Recurrence in Patients With HBV-Related Disease Post Liver Transplantation

Trial Profile

Phase I Study of T Cell Receptor-Redirected T Cells Infusions for Preventing Hepatocellular Carcinoma Recurrence in Patients With HBV-Related Disease Post Liver Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs T cell replacement therapy (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Lion TCR
  • Most Recent Events

    • 01 Jun 2018 New trial record
    • 27 May 2018 According to a Lion TCR media release,the company have raised US$ 20 million in its Series A financing round.The proceeds from this fund raising will be primarily used to advance its on-going clinical trials of LioCyx, including this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top